AEGLEA BIOTHERAPEUTICS INC's ticker is AGLE and the CUSIP is 00773J103. A total of 87 filers reported holding AEGLEA BIOTHERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2022 | $1,185,000 | +912.8% | 515,133 | +1999.6% | 0.00% | – |
Q4 2021 | $117,000 | -36.8% | 24,535 | +5.6% | 0.00% | – |
Q3 2021 | $185,000 | +10.8% | 23,243 | -3.1% | 0.00% | – |
Q2 2021 | $167,000 | -31.3% | 23,993 | -21.9% | 0.00% | – |
Q1 2021 | $243,000 | -7.6% | 30,718 | -8.2% | 0.00% | – |
Q4 2020 | $263,000 | -43.4% | 33,463 | -49.0% | 0.00% | – |
Q3 2020 | $465,000 | -20.9% | 65,559 | +3.2% | 0.00% | – |
Q2 2020 | $588,000 | +147.1% | 63,523 | +24.5% | 0.00% | – |
Q1 2020 | $238,000 | -51.0% | 51,003 | -20.0% | 0.00% | – |
Q4 2019 | $486,000 | +817.0% | 63,769 | +805.3% | 0.00% | – |
Q3 2019 | $53,000 | -53.9% | 7,044 | -58.4% | 0.00% | – |
Q2 2019 | $115,000 | -37.2% | 16,942 | -25.8% | 0.00% | – |
Q1 2019 | $183,000 | +28.0% | 22,845 | +19.0% | 0.00% | – |
Q4 2018 | $143,000 | -78.6% | 19,204 | -72.6% | 0.00% | – |
Q3 2018 | $669,000 | -82.7% | 70,142 | -80.8% | 0.00% | -100.0% |
Q2 2018 | $3,868,000 | +386700.0% | 365,697 | +71605.3% | 0.00% | – |
Q2 2017 | $1,000 | -97.2% | 510 | -89.7% | 0.00% | – |
Q1 2017 | $36,000 | +800.0% | 4,959 | +436.1% | 0.00% | – |
Q2 2016 | $4,000 | – | 925 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Yu Fan | 112,044 | $891,000 | 15.31% |
Aisling Capital Management LP | 1,691,151 | $13,445,000 | 2.68% |
GREAT POINT PARTNERS LLC | 900,000 | $7,155,000 | 1.67% |
Bain Capital Life Sciences Investors, LLC | 2,847,689 | $22,639,000 | 1.40% |
Altium Capital Management LP | 609,689 | $4,847,000 | 1.27% |
Sio Capital Management, LLC | 446,000 | $3,546,000 | 1.13% |
UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO | 245,678 | $1,953,000 | 1.12% |
Samsara BioCapital, LLC | 883,720 | $7,026,000 | 1.10% |
Lion Point Capital, LP | 300,000 | $2,385,000 | 0.45% |
Abingworth LLP | 240,500 | $1,912,000 | 0.43% |